Expert Perspectives on Perioperative Immunotherapy in Resectable Stage-III NSCLC

Data from the phase 1/2 ALKOVE-1 trial support the breakthrough therapy designation for NVL-655 in advanced ALK-positive non–small cell lung cancer.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Phase 2 data support additional investigation of lifileucel as a treatment for patients with metastatic non–small cell lung cancer.

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

T-DXd given at 2 dose levels continued to show anti-tumor activity in patients with HER2-overexpressing non–small cell lung cancer.

Those who have been previously treated for KRAS G12C–mutated advanced NSCLC may benefit from treatment with glecirasib.